{"id":206202,"date":"2026-01-27T09:41:49","date_gmt":"2026-01-27T08:41:49","guid":{"rendered":"https:\/\/efecomunica.efe.com\/?p=206202"},"modified":"2026-01-27T10:19:36","modified_gmt":"2026-01-27T09:19:36","slug":"boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease","status":"publish","type":"post","link":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease\/","title":{"rendered":"Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease"},"content":{"rendered":"<p>Statement issued by the company (Announcement)<\/p>\n<div>\n<ul>\n<li><b>Novel\u00a0<\/b><b>TL1A\/IL23p19\u00a0<\/b><b>b<\/b><b>ispecific antibody\u00a0<\/b><b>targets driv<\/b><b>ers<\/b><b>\u00a0<\/b><b>of\u00a0<\/b><b>disease pathogenesis\u00a0<\/b><b>to\u00a0<\/b><b>overcome the\u00a0<\/b><b>efficacy\u00a0<\/b><b>ceiling\u00a0<\/b><b>in<\/b><b>\u00a0inflammatory bowel disease<\/b><b>.<\/b><b>\u00a0<\/b><\/li>\n<li><b>License and collaboration agreement strengthen Boehringer\u2019s inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset.<\/b><\/li>\n<li><b>Boehringer receives global rights to the asset, excluding greater China;\u00a0<\/b><b>Simcere<\/b><b>\u00a0is eligible to receive payments\u00a0<\/b><b>of\u00a0<\/b><b>up to EUR 1<\/b><b>,<\/b><b>0<\/b><b>5<\/b><b>8<\/b><b>\u00a0million<\/b><b>\u00a0<\/b><\/li>\n<\/ul>\n<p>Boehringer Ingelheim and Simcere Pharmaceutical Group Ltd. (\u201cSimcere\u201d) (HKEX: 2096), today announced a license and collaboration agreement to develop SIM0709, a pre-clinical TL1A\/IL23p19 bispecific antibody from Simcere, for the treatment of inflammatory bowel disease (IBD).<\/p>\n<p>Globally, it is estimated that more than\u00a0three\u00a0million people are affected by\u00a0IBD, a\u00a0lifelong, progressive\u00a0condition leading\u00a0to\u00a0frequent\u00a0hospitalization\u00a0and\u00a0surgeries, significantly\u00a0impacting\u00a0patients\u2019 quality of life.\u00a0Current medical options cannot fully prevent or reverse these complications, leaving a clear unmet need. Through this\u00a0partnership,\u00a0Boehringer and\u00a0Simcere\u00a0aim\u00a0to advance\u00a0an\u00a0innovative approach\u00a0to potentially\u00a0redefine treatment possibilities and improve outcomes for patients worldwide.<\/p>\n<p>SIM0709 is a long-acting humanized bispecific antibody developed by\u00a0Simcere\u00a0using\u00a0its\u00a0proprietary multi-specific antibody platform. It\u00a0simultaneously targets tumor necrosis factor ligand superfamily member 15 (TL1A) and interleukin-23 (IL-23), thereby blocking two core pathways that drive the onset and progression of IBD. In both in vitro primary cell studies and in vivo animal studies, SIM0709 demonstrated superior synergistic efficacy, even outperforming the combination of the two corresponding monotherapies.<\/p>\n<p>Carine Boustany, US Innovation Unit Site Head and Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim said,\u00a0\u201cIn IBD, too many patients\u00a0continue to progress\u00a0and experience severe complications\u00a0despite currently available anti-inflammatory therapies. We are\u00a0excited to join forces with\u00a0Simcere\u00a0to accelerate\u00a0the development of this\u00a0therapeutic\u00a0as a potential life changing\u00a0option\u00a0for patients living\u00a0with IBD.\u201d<\/p>\n<p>\u201cSimcere\u2019s\u00a0bispecific antibody\u00a0SIM0709\u00a0was engineered\u00a0with our\u00a0proprietary multi-specific antibody platform\u00a0with\u00a0first-in-class potential for IBD treatment. Partnering with Boehringer Ingelheim, with its long\u2011term commitment and deep\u00a0expertise\u00a0in immunology, positions\u00a0the\u00a0compound\u00a0for rigorous global development,\u201d said\u00a0Gaobo\u00a0Zhou,\u00a0Chief Investment Officer,\u00a0Simcere\u00a0Pharmaceutical Group.\u00a0\u201cTogether we aim to\u00a0accelerate the clinical development and\u00a0advance a treatment option that could improve outcomes for\u00a0patients world-wide\u00a0affected by IBD.\u201d<\/p>\n<p>Under the terms of the agreement Boehringer receives global rights to the asset, excluding greater China. Simcere is eligible to receive an upfront payment as well as success-based development, regulatory and sales milestones up to EUR 1,058 million, as well as royalties on net sales outside of the Greater China territory.<\/p>\n<h2>Boehringer Ingelheim<\/h2>\n<p>Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the\u00a0industry\u2019s top\u00a0investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow.\u00a0Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4MBdR9d0_NNwFHUF83nYlKpb2dXVut5QFH02HIyD9xHed8gwOYAw6tP3FsC4xXzr5VwUuV_yz8Yhtj23rhtQWa80YANymoAbyEGdWPWUsbkETFAUB5P4jV_Dhj0EaN03\" target=\"_blank\" rel=\"noopener\">www.boehringer-ingelheim.com<\/a>.<\/p>\n<h2>Simcere\u00a0Pharmaceutical Group\u00a0Limited<\/h2>\n<p>Simcere\u00a0Pharmaceutical Group Limited\uff082096.HK\uff09\u00a0is a pharmaceutical company driven by innovation and focusing on four therapeutic areas including Neuroscience, Oncology, Autoimmune Diseases and Anti-infection. We proactively explore areas with significant unmet needs, and our mission is\u00a0For\u00a0patients, for life.\u00a0Driven\u00a0by\u00a0our\u00a0in-house R&amp; efforts and synergistic innovation,\u00a0Simcere\u00a0has\u00a0established\u00a0strategic\u00a0cooperation\u00a0partnerships\u00a0with\u00a0many\u00a0innovative\u00a0companies\u00a0and\u00a0research\u00a0institutes.\u00a0Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4MBdR9d0_NNwFHUF83nYlMi_7FB9MB4AUi165rYyKDxUcEpAMnkO0o0yRcjUmcp-R38OFQ0rsR-FehM2Py2QRSb3Wphbz9kmUPI8zPkz5lA=\" target=\"_blank\" rel=\"noopener\">www.simcere.com<\/a>.<\/p>\n<p><b>Intended Audiences Notice<\/b><\/p>\n<p>This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.<\/p>\n<p><img \/><em>AGENCIA EFE S.A.U.,S.M.E. shall not be liable for any information contained in this message and assumes no responsibility towards third parties in relation to its contents, being expressly exempt from any liability that the author may have in relation to the information in question. Agencia EFE reserves the right to distribute the press release on the news wire, or to publish it on EFE Comunica.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Statement issued by the company (Announcement) Novel\u00a0TL1A\/IL23p19\u00a0bispecific antibody\u00a0targets drivers\u00a0of\u00a0disease pathogenesis\u00a0to\u00a0overcome the\u00a0efficacy\u00a0ceiling\u00a0in\u00a0inflammatory bowel disease.\u00a0 License and collaboration agreement strengthen Boehringer\u2019s inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset. Boehringer receives [&hellip;]<\/p>\n","protected":false},"author":198164071,"featured_media":48434,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[121851],"tags":[],"class_list":["post-206202","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Boehringer Ingelheim and Simcere partner to advance a treatment<\/title>\n<meta name=\"description\" content=\"Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease\/\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim and Simcere partner to advance a treatment","description":"Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease\/#article","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease\/"},"author":{"name":"EFE","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8"},"headline":"Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease","datePublished":"2026-01-27T08:41:49+00:00","dateModified":"2026-01-27T09:19:36+00:00","mainEntityOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease\/"},"wordCount":736,"publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease\/","url":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease\/","name":"Boehringer Ingelheim and Simcere partner to advance a treatment","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease\/#primaryimage"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","datePublished":"2026-01-27T08:41:49+00:00","dateModified":"2026-01-27T09:19:36+00:00","description":"Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease.","breadcrumb":{"@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease\/#primaryimage","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","width":1200,"height":650,"caption":"El \u00edndice Moneyball de Squawka clasifica a los clubes de la Premier League tomando en cuenta las \u00faltimas cinco temporadas (incluida la 2025\/26)."},{"@type":"BreadcrumbList","@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-and-simcere-partner-to-advance-a-dual-target-antibody-treatment-to-address-unmet-needs-in-inflammatory-bowel-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/efecomunica.efe.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease"}]},{"@type":"WebSite","@id":"https:\/\/efecomunica.efe.com\/#website","url":"https:\/\/efecomunica.efe.com\/","name":"EFE Comunica","description":"Contenidos para empresas","publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/efecomunica.efe.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/efecomunica.efe.com\/#organization","name":"EFE Comunica","url":"https:\/\/efecomunica.efe.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","width":1080,"height":486,"caption":"EFE Comunica"},"image":{"@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/EFEComunicaAgenciaEFE","https:\/\/x.com\/EFEcomunica","https:\/\/www.linkedin.com\/showcase\/efecomunica"]},{"@type":"Person","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8","name":"EFE","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","caption":"EFE"},"sameAs":["http:\/\/efe.com"],"url":"https:\/\/efecomunica.efe.com\/en\/author\/efedesarrollo\/"}]}},"jetpack_featured_media_url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","jetpack_likes_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pcEg1r-RDQ","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/206202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/users\/198164071"}],"replies":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/comments?post=206202"}],"version-history":[{"count":2,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/206202\/revisions"}],"predecessor-version":[{"id":206214,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/206202\/revisions\/206214"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media\/48434"}],"wp:attachment":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media?parent=206202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/categories?post=206202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/tags?post=206202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}